ArticleCancer biomarkers : section A of Disease markers
Detection of methylated SEPT9 DNA in peripheral blood for diagnosis of colorectal cancer.
Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundColorectal cancer (CRC) remains a leading cause of cancer-related death worldwide. Although colonoscopy is effective screening method, its widespread adoption is hampered by poor compliance. Development of patient-friendly screening methods that are minimally invasive is of paramount importance to improve CRC screening participation.MethodsA single-center case-control study was conducted. Blood samples were collected from 119 participants (79 CRC patients, 20 patients with colorectal adenomas, and 20 healthy colonoscopy-negative controls) during May 2023 and March 2025. The methylated SEPT9 (mSEPT9) DNA in peripheral blood was analyzed by droplet digital polymerase chain reaction (ddPCR).ResultsThe sensitivity and specificity of mSEPT9 detection in peripheral blood for diagnosis of all stages of CRC patients was 68.35% and 95.00%, respectively. The positive rate were similar between left-sided CRC and right-sided CRC (65.31% vs 72.41%，p ＞ 0.05). mSEPT9 detection in all healthy people with normal colonoscopy were negative. When mSEPT9 detection was combined with CEA and CA199, positive rate could be raised to 82.67%.ConclusionsBlood-based mSEPT9 detection by ddPCR method is a sensitive and specific method for non-invasive diagnosis of CRC. Combination with CEA and CA19-9 could improve its performance. It may serve as a viable alternative for individuals unwilling or unable to undergo invasive procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.